000294449 001__ 294449
000294449 005__ 20250425152131.0
000294449 0247_ $$2doi$$a10.1159/000541541
000294449 0247_ $$2pmid$$apmid:39362191
000294449 0247_ $$2ISSN$$a0030-2414
000294449 0247_ $$2ISSN$$a1423-0232
000294449 037__ $$aDKFZ-2024-02274
000294449 041__ $$aEnglish
000294449 082__ $$a610
000294449 1001_ $$aKlein, Eva-Maria$$b0
000294449 245__ $$aEfficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma.
000294449 260__ $$aBasel$$bKarger$$c2025
000294449 3367_ $$2DRIVER$$aarticle
000294449 3367_ $$2DataCite$$aOutput Types/Journal article
000294449 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745587250_24420
000294449 3367_ $$2BibTeX$$aARTICLE
000294449 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294449 3367_ $$00$$2EndNote$$aJournal Article
000294449 500__ $$aOncology 2025;103:389–399
000294449 520__ $$aAlthough recent data suggest that melphalan high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT) is safe and effective in eligible multiple myeloma (MM) patients up to the age of 75 years, its value in elderly MM patients is still controversially discussed.We retrospectively analyzed 607 MM patients ≥60 years old, who were admitted to our institution for first-line or salvage HDT/ASCT between January 2007 and October 2018. We assigned them to three groups according to age at HDT/ASCT: 60-64 years (S1), 65-69 years (S2) and ≥70 years (S3). We compared progression-free and overall survival, duration of hospitalization, complications, transfers to intermediate or intensive care unit, readmissions after discharge and deaths within 100 days after HDT/ASCT between these groups.Age did not impact progression-free and overall survival after first-line and salvage HDT/ASCT. Patients ≥70 years old at first HDT/ASCT had a longer hospitalization compared to patients 60-64 years old; however, the difference in the length of hospitalization was only marginal. Rates of febrile neutropenia, mucositis, transfers to intermediate or intensive care unit, readmissions after discharge, and deaths within 100 days after HDT/ASCT were similar in the 3 age groups of patients receiving first or salvage HDT/ASCT. Patients with a Charlson Comorbidity Index ≥2 receiving first HDT/ASCT had a higher risk for a transfer to intermediate or intensive care unit.Our analysis shows that HDT/ASCT is safe and effective in eligible elderly MM patients in first-line treatment and at relapse. A careful patient selection according to biological rather than chronological age is of crucial importance.
000294449 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000294449 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294449 650_7 $$2Other$$aAutologous stem cell transplantation
000294449 650_7 $$2Other$$aElderly patients
000294449 650_7 $$2Other$$aMultiple myeloma
000294449 650_7 $$2Other$$aSurvival
000294449 650_7 $$2Other$$aToxicity
000294449 7001_ $$aHujic, Sejla$$b1
000294449 7001_ $$aMiah, Kaya$$b2
000294449 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b3$$udkfz
000294449 7001_ $$aMerz, Maximilian$$b4
000294449 7001_ $$aBertsch, Uta$$b5
000294449 7001_ $$aWeinhold, Niels$$b6
000294449 7001_ $$aGoldschmidt, Hartmut$$b7
000294449 7001_ $$aSauer, Sandra$$b8
000294449 773__ $$0PERI:(DE-600)1483096-6$$a10.1159/000541541$$gp. 1 - 11$$p389–399$$tOncology$$v103$$x0030-2414$$y2025
000294449 909CO $$ooai:inrepo02.dkfz.de:294449$$pVDB
000294449 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000294449 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000294449 9141_ $$y2024
000294449 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-24$$wger
000294449 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOLOGY-BASEL : 2022$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000294449 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000294449 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000294449 980__ $$ajournal
000294449 980__ $$aVDB
000294449 980__ $$aI:(DE-He78)C060-20160331
000294449 980__ $$aUNRESTRICTED